LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA

LCCC 0424：I 期厄洛替尼每 72 小时给予胶质母细胞瘤患者一次

• 批准号: 7625621
• 负责人: CELESTE M LINDLEY
• 金额: $ 0.41万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625621
• 关键词: Brain Neoplasms; Computer Retrieval of Information on Scientific Projects Database; Dose; Erlotinib; Funding; Glioblastoma; Grant; Hour; Institution; Patients; Phase; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a research study to investigate a new dosing regimen of erlotinib in patients with glioblastoma multiforme, a type of brain tumor, who have failed first line therapy.

这个子项目是众多研究子项目之一